

Resource Summary Report

Generated by [dkNET](#) on Sep 4, 2026

HEK293-EBNA1-6E

RRID:CVCL_HF20

Type: Cell Line

Proper Citation

RRID:CVCL_HF20

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_HF20

Proper Citation: RRID:CVCL_HF20

Description: Cell line HEK293-EBNA1-6E is a Transformed cell line with a species of origin Homo sapiens (Human)

Sex: Female

Defining Citation: [PMID:21356792](#)

Comments: Characteristics: This cell line is transfected with EBNA1t, a truncated version of EBV EBNA1 lacking the Gly-Gly-Ala repeats region. It has an enhanced ability to produce recombinant protein compared to HEK293-EBNA (Cellosaurus=CVCL_6974)., Characteristics: The use of recombinant protein expression vectors containing the EBV oriP in cell lines stably expressing EBV's EBNA1 protein significantly increases recombinant protein yield., Group: Patented cell line.

Category: Transformed cell line

Organism: Homo sapiens (Human)

Name: HEK293-EBNA1-6E

Synonyms: HEK 293EBNA1-6E, HEK 293-6E, HEK293-6E, HEK2936E, 293-6E, 293Fet-clone 6E

Cross References: Wikidata:Q54882446

ID: CVCL_HF20

Hierarchy: cvcl_6642

Record Creation Time: 20220427T220329+0000

Ratings and Alerts

No rating or validation information has been found for HEK293-EBNA1-6E.

No alerts have been found for HEK293-EBNA1-6E.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 158 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Chhan CB, et al. (2026) Transgenic mouse-derived human monoclonal antibodies targeting EBV gp350 and gp42 provide basis for therapeutic development. Cell reports. Medicine, 7(2), 102618.

Hurlburt NK, et al. (2026) Structural basis for antibody cross-neutralization of Dengue and Zika viruses. Communications biology, 9(1).

Wan YH, et al. (2026) Monoclonal neutralizing antibodies elicited by infection with Kaposi sarcoma-associated herpesvirus reveal critical sites of vulnerability on gH/gL. PLoS pathogens, 22(1), e1013772.

McClave MK, et al. (2026) Isolation and characterization of broadly-neutralizing anti-HCMV-gB antibodies from human donors using a prefusion-stabilized HCMV gB variant. PLoS pathogens, 22(2), e1013950.

Carter JJ, et al. (2025) Human monoclonal antibodies to HPV16 show evidence for common developmental pathways and public epitopes. PLoS pathogens, 21(10), e1013086.

Lehky M, et al. (2025) A novel method for recombinant mammalian-expressed S-HBsAg virus-like particle production for assembly status analysis and improved anti-HBs serology. Protein science : a publication of the Protein Society, 34(1), e5251.

Edwards KR, et al. (2024) Vaccination with nanoparticles displaying gH/gL from Epstein-Barr virus elicits limited cross-protection against rhesus lymphocryptovirus. Cell reports. Medicine, 5(6), 101587.

Scharffenberger SC, et al. (2024) Targeting RSV-neutralizing B cell receptors with anti-idiotypic antibodies. Cell reports, 43(10), 114811.

Seifert L, et al. (2023) The classical pathway triggers pathogenic complement activation in membranous nephropathy. Nature communications, 14(1), 473.

Hussack G, et al. (2023) Structure-guided design of a potent *Clostridioides difficile* toxin A inhibitor. *Frontiers in microbiology*, 14, 1110541.

Schaefer-Babajew D, et al. (2023) Antibody feedback regulates immune memory after SARS-CoV-2 mRNA vaccination. *Nature*, 613(7945), 735.

van Houtum EJH, et al. (2023) Tumor cell-intrinsic and tumor microenvironmental conditions co-determine signaling by the glycoimmune checkpoint receptor Siglec-7. *Cellular and molecular life sciences : CMLS*, 80(6), 169.

Roopnarine O, et al. (2023) Fluorescence lifetime FRET assay for live-cell high-throughput screening of the cardiac SERCA pump yields multiple classes of small-molecule allosteric modulators. *Scientific reports*, 13(1), 10673.

Oskam N, et al. (2023) Factors affecting IgG4-mediated complement activation. *Frontiers in immunology*, 14, 1087532.

Sun H, et al. (2023) Protein production from HEK293 cell line-derived stable pools with high protein quality and quantity to support discovery research. *PloS one*, 18(6), e0285971.

Verstraete MM, et al. (2023) Multivalent IgM scaffold enhances the therapeutic potential of variant-agnostic ACE2 decoys against SARS-CoV-2. *mAbs*, 15(1), 2212415.

Guay KP, et al. (2023) ER chaperones use a protein folding and quality control glyco-code. *Molecular cell*, 83(24), 4524.

Korenkov M, et al. (2023) Somatic hypermutation introduces bystander mutations that prepare SARS-CoV-2 antibodies for emerging variants. *Immunity*, 56(12), 2803.

Rodarte JV, et al. (2023) Structures of drug-specific monoclonal antibodies bound to opioids and nicotine reveal a common mode of binding. *Structure (London, England : 1993)*, 31(1), 20.

K??hl L, et al. (2022) The elg technology to generate Ig-like bispecific antibodies. *mAbs*, 14(1), 2063043.